Phaseline

Companies › Quoin Pharmaceuticals

Quoin Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 6 registered trials: 6 Phase 2; Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
QRX003 Lotion 2%
Serine protease inhibitor
–Phase 2Netherton SyndromeDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06953466QRX003 Lotion 2%Phase 2Netherton SyndromeImmunologyDec 2026
NCT05789056QRX003 Lotion 2%Phase 2Netherton SyndromeImmunologyDec 2026
NCT05521438QRX003 Lotion 2%Phase 2Netherton SyndromeImmunologyDec 2026
NCT05521438QRX003 Lotion 2%Phase 2Netherton SyndromeImmunologyDec 2026
NCT05521438QRX003 Lotion 2%Phase 2Netherton SyndromeImmunologyDec 2026
NCT07538583QRX003 Lotion 2%Phase 2Netherton SyndromeImmunologyJan 2027

From the company's SEC filings

Cash and short-term investments of $33m on 2026-09-30; operating cash outflow about $18m a year; runway about 22 months at that burn, to Jul 2028; 4 of 4 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Aclaris Therapeutics Savara Alumis Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S.

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.